IMA vs RTX · rev $9.2M vs P/E 36, rev $88.60B
ImageneBio, Inc. (IMA) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported IMA revenue for 2023-12-31 was $9.2M. Net income was -$68.2M. Revenue was down 41.3% from 2022-12-31 to 2023-12-31. IMA currently screens at market cap $64.7M.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
IMA currently screens at market cap $64.7M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the IMA and RTX stock pages for the full models.
Not investment advice.